Two weeks after Bristol-Myers Squibb (BMS) Co.'s historic $74 billion takeover bid, Celgene Corp. went on its own dealmaking spree, adding pacts with Kyn Therapeutics Inc. and Obsidian Therapeutics Inc. to its immuno-oncology (I-O) fold. Celgene, of Summit, N.J., gained an exclusive option to aryl hydrocarbon receptor (AHR) antagonist and kynurenine-degrading enzyme, or Kynase, programs from Kyn in return for $80 million up front, an equity stake and undisclosed milestone payments and sales royalties. The deal with Obsidian – financials entirely undisclosed – entails a multiyear collaboration that entitles Celgene to exclusive options to license cell therapies that use Obsidian's Destabilizing Domain (DD) technology to modulate IL-12 and CD40L activity.